Cicloxolone sodium (CCX) is a broad spectrum antiviral agent which has a largely non-specific and complex mode of antiviral action. However, the experimental finding that herpes simplex virus type 2 (HSV-2) (strain HG52) is consistently more sensitive to inhibition by CCX than HSV-1 (ll7syn ÷) additionally implies the specific involvement of HSV genes. HSV-1/ HSV-2 intertypic recombinants have been utilized to investigate this genetic difference by comparing their CCX EDso concentrations. No short stretch of HSV-2 DNA was associated with its greater sensitivity to CCX, implying that two or more non-contiguously located HSV genes are involved. Correlating CCX sensitivity with recombinant virus genome structures allowed separate evaluation of the gene regions encoding glycoproteins gB, gC, gD, gE, gG, gH and gI and this suggests that the gene locations encoding gH and gC determine the CCX sensitivity difference. The selective inhibitor of Golgi apparatus glycosylation, monensin, gave results analogous to those obtained with CCX.
Introduction
Sensitivity to the triterpenoid compound cicloxolone sodium (CCX) has been reported for several members of the herpesvirus family (Dargan & Subak-Sharpe 1985; Gait et al., 1990) . When cell cultures infected with herpes simplex virus type 1 (HSV-1), HSV-2, human cytomegalovirus, varicella-zoster virus, equine herpesvirus type 1 and bovine herpesvirus type 1 are treated with 300 ~tM-CCX, a reduction in infectious virus yield is obtained within the range of 100-to 100000-fold (Dargan & Subak-Sharpe, 1985; Gait et al., 1990) . CCX also inhibits the growth of viruses which belong to several other virus families including rhabdoviruses, myxoviruses, picornaviruses, bunyaviruses and reoviruses; the only virus tested so far whose growth did not appear to be inhibited by the drug was Semliki Forest virus, a togavirus (Gait et al., 1990) . This broad spectrum antiviral activity of CCX is considered to derive from non-specific drug-induced disturbances in the normal functioning of particular cell membrane processes which are also essential for virus growth (Dargan & Subak-Sharpe, 1986a, b) .
Electron microscope studies of uninfected BHK and Flow 2002 cells treated with CCX have revealed morphological changes affecting the plasma membrane, rough endoplasmic reticulum and Golgi apparatus 0000-9846 © 1991 SGM (unpublished observations). Thus, ultrastructural changes correlate with the alterations in cell membraneassociated biochemical functions that have been reported as being CCX-induced: an increase in the protein permeability of the plasma membrane, a decrease in the level of protein synthesis, changes in the normal nuclear/cytoplasmic distribution of some HSV proteins, a decrease in the post-translational processing of some HSV proteins (especially glycosylation and sulphation) and a reduction in the amounts of HSV glycoproteins expressed on the infected cell surface (Dargan & SubakSharpe, 1985 , 1986a unpublished observations) . This drug-induced antiviral activity through cell membrane disturbance has, in some cell lines, a simultaneous cytotoxic effect. However, the magnitude of the cytotoxic effect varies widely between different cell lines and we have identified several lines, including the human Flow 2002 line used in this study, in which the antiviral and cytotoxic effects are uncoupled (Dargan & SubakSharpe, 1985; Gait et al., 1990) .
The anti-HSV effect of CCX operates principally at the level of particle assembly and maturation. In the presence of the drug HSV particle yields are not only reduced but more importantly exhibit a dramatically increased particle/p.f.u, ratio; i.e. there is a great loss of virus quality (Dargan & Subak-Sharpe, 1985; Dargan et al., 1988) . Qualitative differences in polypeptide content have been shown by comparing the yields of virus particles purified from CCX-treated cultures and controis (Dargan & Subak-Sharpe, 1986a) . This effect of the drug on the constituent polypeptides of the virion correlates with the loss of infectivity. However, it is not known which of the many qualitative and quantitative changes in the structural polypeptide content of virions are important for the loss of infectivity.
Although there is extensive evidence that the major antiviral activity of CCX is non-specific and executed through its interaction with cell membrane systems utilized during viral replication, we have consistently observed that HSV-2 (strain HG52) is more sensitive than HSV-1 (strain 17), indicating that there is also a specific anti-HSV effect of CCX. This HSV typedifferential sensitivity to CCX has been confirmed with several different HSV-1 and HSV-2 strains (Dargan & Subak-Sharpe, 1985) . Our present study investigates the genetic basis for this observation and provides evidence that differences in, or very close to, the glycoprotein genes identified in HSV-1 as UL22 (gH) and UL44 (gC) (McGeoch et al., 1988) are responsible.
Methods
Cells. The human cell line Flow 2002 was used throughout. Cells were grown in Eagle's medium (Glasgow modification) supplemented with 10 % foetal calf serum and 1% non-essential amino acids (Gibco). After cells had been infected with HSV, 5% human serum was substituted for foetal calf serum (Ehu 5) to limit satellite plaque formation.
Virus. The viruses used were HSV-1 strain 17 syn +, HSV-2 strain HG52 (Brown et al., 1973; Timbury, 1971) and various HSV-I (17)/HSV-2 (HG52) intertypic recombinants (see Fig. 2 ).
Drug preparation. Preparations (10 raM) of CCX were freshly made for each experiment with sterile distilled water and diluted 1:l with sterile 10 % bovine serum albumin which stabilizes the drug in solution. Monensin (Mon) (Sigma) was prepared as a 10 mM stock solution in ethanol; subsequent dilutions were prepared in Eagle's medium.
Estimation of EDso values.
Cell monolayers (4 × 106 cells) on 50 mm dishes were infected with between 200 and 400 p.f.u. HSV-1, HSV-2 or the specified intertypic HSV-1/HSV-2 recombinant viruses. After absorbing for 1 h at 37 °C, unbound virus was removed by two washes with Ehu 5. Cultures were then overlaid with Ehu 5, either without addition of drug, or containing increasing concentrations of CCX or Mon. At 48 h post-infection the infected monolayers were fixed and stained and the number of plaques/dish were counted. The CCX or Mon concentrations corresponding to the EDs0 were obtained by interpolation from the plotted data (Fig. 1) . 
Results
The dose-response curves obtained with CCX and Mon ( Fig. 1) showed that the growth of HSV-2 is more sensitive than that of HSV-1 to inhibition by either compound. Estimation of EDs0 values for CCX (EDs0CCX) or Mon (EDsoMon) allowed the quantification of HSV-1 and HSV-2 drug sensitivities. Within individual experiments the EDsoCCX and EDsoMon values obtained showed little replicate variability and HSV-2 was invariably more sensitive to either drug than HSV-1 (Table 1) . Comparison of EDsoCCX and EDs0Mon obtained for each virus on different occasions, however, revealed substantial inter-experimental variation. The source of this variation is not known but the mechanism of antiviral activity proposed for CCX (Dargan & Subak-Sharpe, 1986a) suggests that differences in the physiological state of the cells used in each experiment could strongly influence the EDso values obtained. Although the actual EDs0 concentrations varied between experiments it should be noted that the ratio of EDs0 HSV-1 :EDso HSV-2 for either drug was reasonably consistent (Table 1) .
In order to locate and identify the HSV-2 genetic information responsible for increased sensitivities to CCX or Mon the sensitivities to each drug of 20 intertypic recombinants ( Fig. 2) were estimated in experiments which were always individually controlled. Recombinant viruses with either the HSV-1 or HSV-2 genetic information specifying sensitivity to CCX or Mort were identified by the tendency of their EDso values to approximate the HSV-1 or HSV-2 control values within each experiment. In general, the approximation of particular recombinants to the HSV-1 or HSV-2 values was reproducible. To aid comparison between different experiments and between the data obtained with CCX (Table 2a) or with Mort (Table 2b) , the obtained values were scaled using the formula: scale value = [(EDso recombinant-EDso HSV-2)/(ED5o HSV-1-EDs0 HSV-2)]+ 1. This formula fixes the theoretical scale value as 2 for HSV-I and 1 for HSV-2. Consequently, experimental scale values of > 1.5 were taken to indicate that the recombinant possessed the HSV-1 genetic information and values of < 1.5 indicated the presence of HSV-2 genetic information specifying greater sensitivity to the drugs.
Although there were a small number of aberrant results (for CCX four/77 and for Mon six/71) the data as a whole are convincingly consistent, justifying firm conclusions. On the basis of their sensitivity to CCX (Table 2a) or to Mon (Table 2b) , individual recombinants were identified as similar to HSV-1 [RH2, RE6, RA1, RH6, RH31, RHt, BX6(17q), RD6 and RD1] or HSV-2 [R5-4, DXI(31), FX9(5-8), R13-2, R12-5, R5-1, RA5, 17Xll, ]. The sensitivity to CCX of all intertypic recombinants corresponded consistently with their sensitivity to Mon, implicating involvement of the same genetic information. When the above results deduced from Table 2(a) and (b) are considered with the genome type composition of the recombinants (Fig. 2) , we are forced to conclude that no single short stretch of DNA can account for the higher HSV-2-associated sensitivity to CCX and/or Mon; this implies that two or more non-contiguously Marsden et al., 1978; Preston et al., 1978; Chartrand et al., 1979 Chartrand et al., , 1981 Brown et al., 1984) .
located genes (or gene clusters) are involved.
Since both Mon (Johnson & Spear, 1982; Kousoulas et al., 1983) and CCX (Dargan & Subak-Sharpe, 1986a) inhibit the maturation of HSV glycoproteins within the Golgi apparatus, the glycoprotein genes were regarded as the most likely candidates to be involved in drug sensitivity. To investigate whether any and, if so, which of the glycoproteins specified by HSV can be associated with the more sensitive phenotype of HSV-2, the serotype of the seven glycoproteins encoded by every recombinant was deduced. In the majority of cases the serotype of all seven glycoproteins could be inferred directly from the genome structures (Fig. 2) or had already been ascertained. In 10 instances, certain individual glycoprotein genes were located within, or close to, the region of uncertainty surrounding an HSV-1/HSV-2 genetic cross-over site and here identification of the serotype of the relevant glycoprotein depended upon interaction of the glycoprotein with an HSV type-specific monoclonal antibody (MAb). Buckmaster et al. (1984) reported the serotypes of gH encoded by intertypic recombinants R5-4, RH6 and R12-5, obtained by virus neutralization with the MAb LPll, directed against gH-1. Neutralization of virus infectivity by MAb LP 11 has been used by us to resolve the gH serotype encoded by recombinants FX5-12 and RA5 (data not shown). Buckmaster et al. (1984) also identified the serotype of gB encoded by recombinants FX9(5-8), R5-4, RH6, RH31 and R12-5 by using MAb B3, directed against gB-1, in solid-phase radioimmunoassays. The gB serotype encoded by recombinants FX5-12, RA5 and RH1 has been identified by us using MAb B 3 in immunoprecipitations (data not shown). Immunoprecipitations using a MAb directed against gC-1 (1001) disclosed the gC serotype of recombinants BX6(17-1), R12-5, FX9(5-8), RH31 and R13-2 (data not shown). It should be appreciated that in each of these cases the MAb recognition refers to a particular epitope of the glycoprotein. Table 3 summarizes the glycoprotein serotypes for all seven genes for every recombinant and shows that the genetic determinant regions encoding gB-2 (RA1 and RH6), gG-2, gD-2, gI-2 and gE-2 [RH1, BX6(17-1) and RD6) do not contribute in any major way to the greater drug sensitivity of HSV-2. Furthermore, the whole short region of HSV-1 (R12-5) failed to impart the less sensitive HSV-1 phenotype. Only the gH-2 and gC-2 determinant regions appear to have a significant role in the increased sensitivity of HSV-2 to CCX and Mon. Where both the gH and gC determinant regions derived from HSV-1 [recombinants RH2, RD1, RE6, RH31, RA1, RH6, RH1, BX6(17-1) and RD6], every virus exhibited HSV-1 sensitivity to both drugs and, where both the gH and gC genetic regions derived from HSV-2 [R12-5, R13-2, R6-26 and DXl(32)], the viruses showed the more sensitive HSV-2 phenotype. Those recombinants in which either gH or gC are derived from the HSV-2 genome, irrespective of which of the two gene regions is present [R5-4, R5-1, FX5-12, DXI(31), FX9(5-8), 17Xll and RA5], all exhibited the more sensitive HSV-2 phenotype. Thus, HSV sensitivity dominates over insensitivity to the drugs. It can be concluded that the genome regions encoding glycoproteins gH and gC appear to play an equally important role in determining the greater sensitivity of HSV-2 to CCX and Mon.
In a further experiment, EDsoCCX and ED50Mon for HSV-1 (KOS), a gC-mutant of HSV-1 (KOS) [HSV-1 (gC-39) (Holland etal., 1984; Homa etal., 1986) ], HSV-1 (17) and HSV-2 (HG52) were determined and the results are given in Table 4 . As can be seen, HSV-1 (gC-39) behaved exactly like a normal HSV-1 strain.
Discussion
The finding that HSV-2 is more sensitive than HSV-1 to inhibition by CCX and carbenoxolone sodium (CBX) has been amply documented (Dargan & Subak-Sharpe, 1985; Dargan et al., 1988) . We have now shown that this sensitivity difference similarly applies to inhibition by Mon, a compound known to block certain glycosylation steps which occur in the Golgi apparatus. Treatment of cells with Mon results in disruptive vacuolation of the Golgi complex with concomitant inhibition of glycoprotein processing (Griffiths et al., 1983; Boss et al., 1984) . We also report that the sensitivity of 20 intertypic recombinants to CCX corresponds exactly to their sensitivity to the unrelated compound Mon. This strongly suggests that the genetic basis for the HSV-1/ HSV-2 sensitivity difference to CCX and Mon is the same. The anti-HSV effect of Mon has been extensively investigated by others and shown to derive from specific inhibition of HSV glycoprotein processing at the level of the Golgi apparatus (Johnson & Spear, 1982 Kousoulas et al., 1983; Ghosh-Choudhury et al., 1987) . A major component of the anti-HSV activity of CCX, which has been shown to have a complex, broadly nonspecific mode of action due to perturbations at the level of cell membranes, manifests as strong inhibition of virus glyeoprotein processing (Dargan & Subak-Sharpe, 1986a, b) .
Our earlier experiments showed that CCX inhibits the glycosylation of HSV glycoproteins in a biphasic manner. At relatively low drug concentrations, the maturation of the oligosaccharide chains within the Golgi apparatus complex is substantially reduced but at higher concentrations (> 100 ~tM) the initial processing step within the lumen of rough endoplasmic reticulum, whereby sugars are N-linked to the polypeptide backbone, is also inhibited (Dargan & Subak-Sharpe, 1986a) . Electron microscope studies, currently in progress, reveal a high level of vacuolation within CCX-treated BHK and Flow 2002 cells, reminiscent of the disruptive vacuolation reported following treatment with Mort. We are trying to obtain conclusive evidence whether or not the vacuoles derive from Golgi membrane.
The data of Table 2 (a) and (b) provide compelling evidence that the increased sensitivity of HSV-2 to both CCX and Mon is determined by the same viral information. Scrutiny of the glycoprotein serotype maps for the 20 intertypic recombinants shown in Table 3 indicates that the drug sensitivity difference maps to the locations 0.288 to 0.315 map units (m.u.) (RH6 and R5-4) and 0-6 to 0-688 m.u. [BX6(17-1) and R13-2]. The DNA sequences present within these two regions encode, respectively, not only genes UL22 (gH) and UL44 (gC) but also adjacent genetic information, and it is possible that the activity of such closely linked genes explains the greater CCX and Mon sensitivity of HSV-2. However, the analogous effects of CCX and Mon on glycoprotein processing highlight genes UL22 and UL44 as the most likely candidates. Small modulating effects due to one or other of the remaining five HSV glycoprotein genes could have gone undetected by our experimental analysis and therefore cannot be ruled out.
Our data argue against an interaction between glycoproteins gH and gC giving either sensitivity or low sensitivity. Sensitivity due to such interaction is ruled out by recombinants R5-4, R5-1, FX5-12, DXI(31), FX9(5-8), 17Xll and RAS. Low sensitivity determined by interaction between UL22 and UL44 is ruled out by the gC deletion mutant gC-39 (Table 4) . We conclude that typical HSV-2 sensitivity to CCX and Mon prevails provided that at least one of the HSV-2 determinant regions containing gH or gC is present. Assuming that the sensitivity difference operates through the functioning of either the gC or gH equivalent HSV-2 locus, it is difficult to identify how the sensitivity determination operates in the light of what we know about the functioning of either glycoprotein, gC, which is a virion component, is dispensable and has been shown to be involved in several different functions, gC-I and gC-2 bind the C3b component of complement (McNearney et al., 1987; Seidel-Dugan et al., 1990) and thus may have a role in protecting virus from macrophage attack and/or in protecting infected cells from complement-mediated lysis, gC seems to have a role in modulating both HSV adsorption to cell surfaces and in virus penetration into cells; recent data from Langeland et al. (1990) show that although gC is not strictly required for adsorption to the cell receptor(s), the gC-mutant gC-39 exhibits slower kinetics of adsorption compared to wild-type virus, implying that gC has a facilitating role in adsorption. De Luca et al. (1982) and Epstein et al. (1984) have shown that viruses having a low gC : gB ratio, or which lack gC entirely, have a faster rate of penetration, which suggests that gC has a modulating role in the penetration process.
Although no HSV-2 homologue of HSV-1 gH has yet been reported, the gene has been identified in the DNA sequence of HSV-2 (HG52) (D. McGeoch, personal communication), gH-1 is known to be essential and to have several functions: it is a structural component of the virus particle which also plays a part in virus entry (Buckmaster et al., 1984; Gompels & Minson, 1986; Desai et al., 1988) ; it has a role, along with gD and gB, in HSV penetration (Fuller et al., 1989) ; and it has a role in virus egress from infected cells (Buckmaster et al., 1984; Gompels & Minson, 1986) . The glycosylation, folding and transport of gH to the cell surface appears to involve other virus products (Gompels & Minson, 1989) .
It seems possible that gC and gH have alternative roles at the level of penetration and that changes in the glycosylation status of either HSV-2 glycoprotein affects this process to a greater extent than the analogous changes in the HSV-I equivalent; an alternative possibility is that these greater effects on gC-2 and gH-2 manifest particularly in terms of differential virus quality of assembled progeny virions. The data published by would support this view (in Dargan & Subak-Sharpe, 1985, Table 4 , the particle/infectivity ratios with 200 p.M-CBX increase fivefold and 25-fold for HSV-1 and HSV-2, respectively, and, with 150 and 200 ~tM-CCX, 83-versus 760-fold and 71-versus 930-fold respectively; Table 5 , which gives independent CCX determinations for cell-associated and cell-released virus, gives further support at concentrations of 50 and 100 ~M-CCX).
Our thanks are due to Miss L. Baxendale and Dr P. C. Thornton of the Biorex Laboratories Company Ltd for generously supplying us with cicloxolone sodium. We also thank Dr A. C. Minson, Dr M. Levine and Dr A. Cross for supplies of monoclonal antibodies LPI 1, B 3 and 1001 respectively.
